Compare Byrna Technologies Inc (BYRN) vs Medtronic PLC (MDT) Price & Performance

BYRN trades at $4.32, down 10.93% amid weak Q2 2026 results, with revenue declining 42.5% and a significant EPS miss. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with negative net income and ROE. Recent management changes and marketing initiatives aim to address sales challenges, while an ongoing legal investigation adds uncertainty.

The outlook is mixed; analyst consensus is 71% buy with potential from new leadership and product expansion, but execution risk is high given profit declines and competitive pressures. Investors should weigh turnaround efforts against persistent operational weaknesses and legal overhangs for near-term volatility.

Medtronic (MDT) trades at $90.70, up 1.44% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.55 beating expectations of $1.54. Revenue growth accelerated to $33.54 billion in 2025 with improving profit margins of 13.2%. Recent positive developments include new product approvals and institutional accumulation, though RSI levels suggest potential near-term overbought conditions.

The outlook remains positive with analyst consensus targeting $98.75 (8.9% upside) and no sell ratings. Key opportunities include robotic surgery platform expansion and cardiac ablation growth, while risks involve rising debt levels and competitive pressures. The stock offers dividend stability with a $0.72 upcoming payment, making it attractive for income-focused investors seeking medical technology exposure.